CA Patent

CA2597016A1 — Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine

Assigned to Bioprojet SC · Expires 2006-08-17 · 20y expired

What this patent protects

New salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine. The inventio n relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidin e monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

USPTO Abstract

New salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine. The inventio n relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidin e monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Drugs covered by this patent

Patent Metadata

Patent number
CA2597016A1
Jurisdiction
CA
Classification
—
Expires
2006-08-17
Drug substance claim
No
Drug product claim
No
Assignee
Bioprojet SC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.